论文部分内容阅读
目的探讨胸腺肽а1对支气管扩张症患者感染加重期细胞免疫的影响。方法连续纳入2012年1月-2015年1月福建医科大学附属第一医院体检中心健康人员42名作为健康对照组及呼吸与危重症医学科住院治疗并诊断为支气管扩张的感染加重期的患者56例,按病情分为治疗组(胸腺肽α1干预+标准化治疗组)34例与对照组(标准化治疗组)22例,对比2组患者细胞免疫功能的变化,以及预后差异(住院时间、治疗费用)。结果支气管扩张症感染加重期患者CD3、CD4、CD8、NK细胞免疫功能水平较健康对照组均有显著降低,差异有统计学意义(P<0.05);支气管扩张症感染加重期治疗组与对照组患者各自治疗后比治疗前的CD3、CD4、CD8、NK细胞免疫功能水平差异有统计学意义(P<0.05),且治疗组与对照组的治疗后的CD3、CD4、CD8、NK细胞免疫功能水平差异有统计学意义(P<0.05);支气管扩张症感染加重期治疗组与对照组患者的平均住院天数、平均住院费用差异有统计学意义(P<0.05)。结论免疫增强剂胸腺肽α1在支气管扩张感染加重期治疗中的具有重要的辅助作用。
Objective To investigate the effect of thymosin а1 on cellular immunity in patients with bronchiectasis. Methods Forty-two healthy individuals from the First Affiliated Hospital of Fujian Medical University from January 2012 to January 2015 were enrolled as healthy control group and hospitalized patients with respiratory and critical care medicine who were diagnosed as exacerbation of bronchiectasis Cases, according to the disease were divided into treatment group (thymosin α1 intervention + standardized treatment group) 34 cases and control group (standardized treatment group) 22 cases, compared two groups of patients with cellular immune function changes, and prognosis differences (length of stay, treatment costs) . Results The immune function of CD3, CD4, CD8 and NK cells in patients with exacerbation of bronchiectasis were significantly lower than those in healthy controls (P <0.05). The bronchial dilatation in exacerbation group and control group After treatment, the immune function of CD3, CD4, CD8 and NK cells in the patients before treatment were significantly different (P <0.05), and the immune function of CD3, CD4, CD8 and NK cells in the treatment group and the control group after treatment (P <0.05). The mean days of hospitalization and average hospitalization cost of patients with exacerbation of bronchiectasis in treatment group and control group were significantly different (P <0.05). Conclusion Thymosin α1, an immunopotentiator, plays an important supporting role in the treatment of exacerbation of bronchiectasis.